EP Patent

EP0139676B1 — Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins

Assigned to Exegenics Inc · Expires 1992-11-25 · 33y expired

What this patent protects

Production, detection of, and characterization of monoclonal antibodies/hybridoma antibodies (and the corresponding hybridoma cells including derived hybrid cells) which are able to recognize proteins (or part(s) thereof) belonging antigenically to the Human Leukocyte Interferon …

USPTO Abstract

Production, detection of, and characterization of monoclonal antibodies/hybridoma antibodies (and the corresponding hybridoma cells including derived hybrid cells) which are able to recognize proteins (or part(s) thereof) belonging antigenically to the Human Leukocyte Interferon System (HuIFN-alpha) - be the said proteins produced natively (for example by white blood cells) or produced by recombinant techniques (genetic engineering) or produced by peptide derivation of the said proteins or part(s) thereof) - exhibiting the same common antigenic determinant(s) as found to be common in the native HuIFN-alpha system. Such antibodies (or the relevant part(s) thereof) can be used as "universal" antibodies for purification and characterization of all the above mentioned proteins belonging to the HuIFN-alpha system.

Drugs covered by this patent

Patent Metadata

Patent number
EP0139676B1
Jurisdiction
EP
Classification
Expires
1992-11-25
Drug substance claim
No
Drug product claim
No
Assignee
Exegenics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.